These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Gene therapy for heart failure: where do we stand? Naim C; Yerevanian A; Hajjar RJ Curr Cardiol Rep; 2013 Feb; 15(2):333. PubMed ID: 23307169 [TBL] [Abstract][Full Text] [Related]
6. Rescuing the failing heart by targeted gene transfer. Kawase Y; Ladage D; Hajjar RJ J Am Coll Cardiol; 2011 Mar; 57(10):1169-80. PubMed ID: 21371634 [TBL] [Abstract][Full Text] [Related]
7. Benefit of SERCA2a gene transfer to vascular endothelial and smooth muscle cells: a new aspect in therapy of cardiovascular diseases. Lipskaia L; Hadri L; Lopez JJ; Hajjar RJ; Bobe R Curr Vasc Pharmacol; 2013 Jul; 11(4):465-79. PubMed ID: 23905641 [TBL] [Abstract][Full Text] [Related]
8. Gene therapy for the treatment of heart failure: promise postponed. Hulot JS; Ishikawa K; Hajjar RJ Eur Heart J; 2016 Jun; 37(21):1651-8. PubMed ID: 26922809 [TBL] [Abstract][Full Text] [Related]
9. Intramyocardial injection of SERCA2a-expressing lentivirus improves myocardial function in doxorubicin-induced heart failure. Mattila M; Koskenvuo J; Söderström M; Eerola K; Savontaus M J Gene Med; 2016 Jul; 18(7):124-33. PubMed ID: 27203155 [TBL] [Abstract][Full Text] [Related]
10. Gene therapy for heart failure. Greenberg B J Cardiol; 2015 Sep; 66(3):195-200. PubMed ID: 25818479 [TBL] [Abstract][Full Text] [Related]
11. The Current and Future Landscape of SERCA Gene Therapy for Heart Failure: A Clinical Perspective. Hayward C; Banner NR; Morley-Smith A; Lyon AR; Harding SE Hum Gene Ther; 2015 May; 26(5):293-304. PubMed ID: 25914929 [TBL] [Abstract][Full Text] [Related]
13. Advances in gene therapy for heart failure. Fish KM; Ishikawa K Discov Med; 2015 Apr; 19(105):285-91. PubMed ID: 25977191 [TBL] [Abstract][Full Text] [Related]
14. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b). Greenberg B; Yaroshinsky A; Zsebo KM; Butler J; Felker GM; Voors AA; Rudy JJ; Wagner K; Hajjar RJ JACC Heart Fail; 2014 Feb; 2(1):84-92. PubMed ID: 24622121 [TBL] [Abstract][Full Text] [Related]
15. Gene therapy in heart failure. SERCA2a as a therapeutic target. Hayward C; Patel H; Lyon A Circ J; 2014; 78(11):2577-87. PubMed ID: 25327883 [TBL] [Abstract][Full Text] [Related]
16. Targeted sarcoplasmic reticulum Ca2+ ATPase 2a gene delivery to restore electrical stability in the failing heart. Cutler MJ; Wan X; Plummer BN; Liu H; Deschenes I; Laurita KR; Hajjar RJ; Rosenbaum DS Circulation; 2012 Oct; 126(17):2095-104. PubMed ID: 23019291 [TBL] [Abstract][Full Text] [Related]
17. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. del Monte F; Williams E; Lebeche D; Schmidt U; Rosenzweig A; Gwathmey JK; Lewandowski ED; Hajjar RJ Circulation; 2001 Sep; 104(12):1424-9. PubMed ID: 11560860 [TBL] [Abstract][Full Text] [Related]
18. Improved cardiac function after sarcoplasmic reticulum Ca(2+)-ATPase gene transfer in a heart failure model induced by chronic myocardial ischaemia. Xin W; Li X; Lu X; Niu K; Cai J Acta Cardiol; 2011 Feb; 66(1):57-64. PubMed ID: 21446381 [TBL] [Abstract][Full Text] [Related]